Donguibogam Evidence Bridge한국어

Ephedra 麻黃

Pharmaceutical nameEphedrae Herba

Evidence grade: Promisingauto-proposed · unreviewedSafety signal: Harm confirmedMapping confidence: Strong correspondence

The three axes are assessed independently and are never combined into a single score.

KTKP records the origin species as Ephedra sinica Stapf.. It has not yet been cross-checked against the Korean Pharmacopoeia, so the identification confidence is not raised to an official code mapping. The same source species also yields 1 other separately registered drug(s) (Ephedrae Radix), which must not be conflated. The name most used for this taxon in current literature is Ephedra sinica.

Tradition · what the text describes

탕액편

The sub-section within this volume has not been verified against the original text yet.

The KTKP traditional materia medica record (M0001077) gives the origin species as Ephedra sinica Stapf., the part used as 지상부, and the properties as 무독(無毒), 신미고(辛微苦), 온(溫). It lists 방광(膀胱), 폐(肺) as the channels entered. The same record cites the Donguibogam (1613) as the source for its indications.

Properties & channel entry: 무독(無毒), 신미고(辛微苦), 온(溫) · 방광(膀胱), 폐(肺)

Source species: Ephedra sinica Stapf. (지상부)

Read the original: Korean Medicine Classics DB ↗

Modern · documented evidence

Obesityevidence for this indication

Evidence grade: Promisingauto-proposed · unreviewed
  • The indication was derived automatically from the Condition field of 0 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.

Literature

SR 1 · RCT 1 · preclinical 16

1 systematic review(s) and 1 RCT(s) were found. Size and consistency are not yet assessed.

Query used

We publish the exact query behind these counts so you can reproduce them yourself.

SRC:MED AND ((TITLE_ABS:"Ephedra sinica")) AND TITLE_ABS:"Obesity"

Clinical trials

Safety

auto-proposed · unreviewed

  • This signal was read off the NCCIH text by keyword rules. A curator must read the source and confirm it.
  • The KTKP record states the following traditional contraindication: 많은 양을 쓰지 않도록 한다. 표실증(表實證)이 아닌 경우로서 신체허약자(身體虛弱者), 표허자한(表虛自汗), 도한천(盜汗喘), 폐허해수(肺虛咳嗽)에 기(忌)한다. 승압(升壓)작용이 있으므로 고혈압 환자들에 신용(愼用)한다. 실제로 180mmHg 이상일때 epehedrine이 혈압을 상승시키므로 사용을 자제하여야 한다(예 : 오약순기산(烏藥順氣散)사용시).
  • NCCIH states: · The FDA has banned dietary supplements containing ephedrine alkaloids because they have serious safety risks.
  • NCCIH states: Even in relatively low doses and short-term use, ephedra has been linked to harmful effects like high blood pressure, heart attack, seizure, stroke, and psychosis.
  • NCCIH states: Ephedra can be life-threatening or disabling in some people.
  • NCCIH states: There are theoretical reasons to suspect that ephedra might interact with other stimulants like caffeine.
  • NCCIH states: · The use of ephedra during pregnancy or while breastfeeding is considered unsafe.

Adverse-event and toxicity literature

This is not a finding of harm — it lists literature that is retrievable. Read the papers to decide.

Interaction literature

This lists literature that is retrievable — it is not a judgement that an interaction exists. Read the papers to decide.

Sources

Bridges from here

In formulas
계출탕 · 계마각반탕 · 거풍지보단 · 생료오적산 · 방풍통성산
Related patterns
Wind-cold pattern · Wind-heat pattern · Early yang stage pattern · Qi phase pattern